← Back to Clinical Trials
Recruiting NCT07602192

NCT07602192 Quantitative Chest CT and Multi-Omics to Distinguish Asthma From COPD and Predict Treatment Response

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07602192
Status Recruiting
Phase
Sponsor Korea University Guro Hospital
Condition Asthma (Diagnosis)
Study Type OBSERVATIONAL
Enrollment 200 participants
Start Date 2025-12-22
Primary Completion 2027-11-30

Eligibility & Interventions

Sex All sexes
Min Age 19 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 200 participants in total. It began in 2025-12-22 with a primary completion date of 2027-11-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to improve the diagnosis and treatment prediction of asthma and chronic obstructive pulmonary disease (COPD) by combining quantitative chest computed tomography (CT) imaging with multi-omics data. Adults with asthma or COPD will be enrolled and undergo routine clinical evaluations, pulmonary function tests, blood tests, and chest CT scans. Additional samples, such as sputum and microbiome specimens, may also be collected. No experimental drugs or devices will be administered as part of this study. Researchers will analyze CT imaging features together with clinical, laboratory, and biological data to better distinguish asthma from COPD and to identify factors that may predict treatment response. The findings are expected to contribute to more precise and personalized management of chronic airway diseases.

Eligibility Criteria

Inclusion Criteria: * Age ≥19 years * COPD group: post-bronchodilator FEV1/FVC \< 0.70 * Asthma group: clinically confirmed diagnosis of asthma by a physician * Able to provide voluntary written informed consent Exclusion Criteria: * Acute exacerbation or active lower respiratory tract infection (e.g., pneumonia) within the past 4 weeks * Pregnancy or breastfeeding * Inability to undergo chest CT (e.g., poor cooperation or severe medical condition) * Refusal to consent to study procedures

Contact & Investigator

Central Contact

Sang Hyuk Kim, MD

✉ gost702@korea.ac.kr

📞 +82-2-2626-1659

Principal Investigator

Sang Hyuk Kim, MD

PRINCIPAL INVESTIGATOR

Korea University Guro Hospital

Frequently Asked Questions

Who can join the NCT07602192 clinical trial?

This trial is open to participants of all sexes, aged 19 Years or older, studying Asthma (Diagnosis). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07602192 currently recruiting?

Yes, NCT07602192 is actively recruiting participants. Contact the research team at gost702@korea.ac.kr for enrollment information.

Where is the NCT07602192 trial being conducted?

This trial is being conducted at Seoul, South Korea.

Who is sponsoring the NCT07602192 clinical trial?

NCT07602192 is sponsored by Korea University Guro Hospital. The principal investigator is Sang Hyuk Kim, MD at Korea University Guro Hospital. The trial plans to enroll 200 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology